Advanced Therapeutics Adoption Will Transform Preclinical Capabilities

Published
23 Aug 24
Updated
14 Aug 25
AnalystConsensusTarget's Fair Value
US$168.75
7.2% undervalued intrinsic discount
14 Aug
US$156.68
Loading
1Y
-22.4%
7D
5.3%

Author's Valuation

US$168.8

7.2% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on07 May 25
Fair value Decreased 2.96%

Shared on30 Apr 25
Fair value Increased 13%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on23 Apr 25
Fair value Decreased 1.83%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 11%

AnalystConsensusTarget has decreased revenue growth from 1.5% to 0.4%.

Shared on09 Apr 25
Fair value Decreased 4.59%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 1.44%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Decreased 0.60%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on10 Mar 25
Fair value Increased 18%

AnalystConsensusTarget has decreased revenue growth from 2.7% to 1.6%, decreased profit margin from 10.2% to 8.8% and increased future PE multiple from 27.3x to 30.5x.